Full history for every metric is available with a Kvantra account
Gelesis Holdings, Inc. (GLS)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | 11 | 26 | 12 |
| Operating profit | $m | -122 | -66 | |||||
| Net profit | $m | - | - | - | - | -93 | -56 | -50 |
| EPS reported | $ | -0.79 | -0.69 | |||||
| Operating cashflow per share | $ | -1.11 | -1.11 | |||||
| Capex per share | $ | 0.13 | 0.13 | |||||
| FCF per share | $ | -1.24 | -1.24 | |||||
| Free cash flow | $m | -87 | -54 | |||||
| Net debt | $m | 55 | 24 | |||||
| Book value equity | $m | -25 | -19 | |||||
| Book value per share | $ | -0.36 | -0.25 | |||||
| Number of shares | m | 70.3 | 73.33 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.81 | -0.62 | |||||
| P/S LTM | x | 0.79 | 0.96 | |||||
| P/FCF LTM | x | -0.24 | -0.21 | |||||
| EV/EBITDA LTM | x | -0.62 | -0.66 | |||||
| EV/Sales LTM | x | 2.92 | 2.97 | |||||
| Earnings Yield LTM | % | -273.23% | -500.28% | |||||
| FCF Yield | % | -425.41% | -465.67% | |||||
| Quality | ||||||||
| ROE | % | 222.62% | 31.43% | |||||
| ROIC | % | -137.49% | -137.49% | |||||
| Operating margin | % | -472.72% | -472.72% | |||||
| Gross margin | % | -6.95% | -6.95% | |||||
| FCF/Sales | % | -337.05% | -337.05% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +130.37% | -37.75% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.39 | -1.61 | |||||
| Net Debt/EBITDA | x | -0.45 | -0.45 | |||||
| EBIT/Net interest | x | -122.91 | -122.91 | |||||
| Net debt/market cap | % | 268.68% | 209.76% | |||||
| Net debt/Equity | x | -2.19 | -1.31 | |||||
| Gross debt/equity | x | -2.48 | -1.80 | |||||
Company overview
Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Established in 2006, Gelesis Holdings Inc. operates from its headquarters in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Gelesis Holdings, Inc. (GLS)
Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Established in 2006, Gelesis Holdings Inc. operates from its headquarters in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free